These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 2831282)

  • 1. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge.
    van Wyke Coelingh KL; Winter CC; Tierney EL; London WT; Murphy BR
    J Infect Dis; 1988 Apr; 157(4):655-62. PubMed ID: 2831282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys.
    Pennathur S; Haller AA; MacPhail M; Rizzi T; Kaderi S; Fernandes F; Bicha L; Schickli JH; Tang RS; Chen W; Nguyen N; Mathie S; Mehta H; Coelingh KL
    J Gen Virol; 2003 Dec; 84(Pt 12):3253-3261. PubMed ID: 14645907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
    Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.
    Hall SL; Sarris CM; Tierney EL; London WT; Murphy BR
    J Infect Dis; 1993 Apr; 167(4):958-62. PubMed ID: 8383726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.
    Clements ML; Belshe RB; King J; Newman F; Westblom TU; Tierney EL; London WT; Murphy BR
    J Clin Microbiol; 1991 Jun; 29(6):1175-82. PubMed ID: 1650789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses of dairy cattle to parainfluenza-3 virus in intranasal infectious bovine rhinotracheitis-parainfluenza-3 virus vaccines.
    Burroughs AL; Morrill JL; Bostwick JL; Ridley RK; Fryer HC
    Can J Comp Med; 1982 Jul; 46(3):264-6. PubMed ID: 6290012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
    Skiadopoulos MH; Surman SR; Riggs JM; Collins PL; Murphy BR
    J Virol; 2001 Nov; 75(21):10498-504. PubMed ID: 11581420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection from parainfluenza-3 virus and persistence of infectious bovine rhinotracheitis virus in sheep vaccinated with a modified live IBR-PI-3 vaccine.
    Lehmkuhl HD; Cutlip RC
    Can J Comp Med; 1985 Jan; 49(1):58-62. PubMed ID: 2985216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
    Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A serologic epidemiological study of parainfluenza 1, 2, and 3 viruses in beef cattle and calves in Illinois.
    Karim A; Ghoneim NH; Woods GT; Mansfield ME; Brown JR
    Res Commun Chem Pathol Pharmacol; 1985 Mar; 47(3):437-40. PubMed ID: 2986256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
    Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
    Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the attenuated vaccine Para-Ribovac.
    Kita J; Oyrzanowska J; Prandota J
    Zentralbl Veterinarmed B; 1983 Aug; 30(7):502-11. PubMed ID: 6316694
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
    Spriggs MK; Collins PL; Tierney E; London WT; Murphy BR
    J Virol; 1988 Apr; 62(4):1293-6. PubMed ID: 2831389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoproteins of human parainfluenza virus type 3: characterization and evaluation as a subunit vaccine.
    Ray R; Brown VE; Compans RW
    J Infect Dis; 1985 Dec; 152(6):1219-30. PubMed ID: 2999259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.
    Karron RA; Wright PF; Hall SL; Makhene M; Thompson J; Burns BA; Tollefson S; Steinhoff MC; Wilson MH; Harris DO
    J Infect Dis; 1995 May; 171(5):1107-14. PubMed ID: 7751684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parainfluenza virus immunization. IV. Simultaneous immunization with parainfluenza types 1, 2, and 3 aqueous vaccines.
    Fulginiti VA; Amer J; Eller JJ; Joyner JW; Askin P
    Am J Dis Child; 1967 Jul; 114(1):26-8. PubMed ID: 4378106
    [No Abstract]   [Full Text] [Related]  

  • 19. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection.
    Durbin AP; Elkins WR; Murphy BR
    Vaccine; 2000 May; 18(22):2462-9. PubMed ID: 10738104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.